Find Clinical Trials & Studies

Lupus Nephritis Phase 2 study of rapcabtagene autoleucel in SLE patients with active, refractory LN

I'm Interested!
Please call
1-833-78TRIAL

A Phase 2, adaptive, randomized, open-label, assessor blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)

  • Sex: Any
  • Age: Adult (18 - 64)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase II
  • Conditions Being Studied: Systemic Lupus Erythematosus

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel following the selected lymphodepletion regimen versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).

Who Can Participate

Age: 18 - 65 years old

Principal Investigator
Ansaam Daoud MD
Department/Division
Medicine (Rheumatology)
  • UH IRB: SITE00002500
  • StudyID: 2025-01713
  • ClinicalTrials.gov: N/A
I'm Interested!
Please call
1-833-78TRIAL

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL

Cancer Trials: 1-866-373-1464